Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript
Wave Life Sciences presents a high-risk profile, with its financials dominated by extreme revenue volatility from non-recurring licensing events rather than a stable commercial base, as evidenced by quarterly swings from -$7.7M to $83.7M.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 27, 2026 | -$0.30+8.8% vs -$0.33 | $13M+191.6% vs $5M |
Q3 2026 Jul 30, 2026 | -$0.34-13.4% vs -$0.30 | $2M-69.5% vs $7M |
Q2 2026 Apr 28, 2026 | -$0.13+61.8% vs -$0.34 | $38M+352.6% vs $8M |
Q1 2026 Feb 26, 2026 | -$0.30-7.1% vs -$0.28 | $17M+7.4% vs $16M |
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript
WAVE Life Sciences NASDAQ: WVE used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant, while also providing updates on its RNA interference, extrahepatic delivery and bifunctional oligonucleotide platforms.

Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript
WAVE Life Sciences NASDAQ: WVE reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver disease.
Benchmark WVE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Wave Life Sciences Ltd. (WVE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.84 | $546.42M | -2.75 | -60.55% | -296.86% | -44.48% | — | |
| $14.77 | $1.56B | 106.03 | 15.58% | 0.75% | 1.04% | — | |
| $26.96 | $4.48B | -8.20 | 33.87% | -56.9% | -120.44% | — | |
| $42.99 | $6.06B | -8.41 | -45.65% | -160.64% | -172.62% | — | |
| $9.78 | $1.1B | -3.22 | 16.92% | -805.75% | -64.73% | — | |
| $20.65 | $2.12B | -20.19 | 120.01% | -73.04% | -9.69% | — |
Wave Life Sciences Ltd. (WVE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Wave Life Sciences Ltd. (WVE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 26, 2026·SEC
May 18, 2026·SEC
Get notified when WVE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Wave Life Sciences Ltd. (WVE) stock FAQ — growth, dividends, profitability & financials explained
Wave Life Sciences Ltd. (WVE) reported $70.9M in revenue over the trailing twelve months. Revenue was $42.7M in fiscal year 2025.
Wave Life Sciences Ltd. (WVE) revenue fell by 35.1% over the trailing twelve months, compared with the twelve months before.
No. Wave Life Sciences Ltd. (WVE) reported a net loss of $210.5M over the trailing twelve months.
Wave Life Sciences Ltd. (WVE) had a return on equity (ROE) of -44.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Wave Life Sciences Ltd. (WVE) had negative free cash flow of $201.5M over the trailing twelve months.